These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31540406)

  • 21. [BRAF gene mutation in thyroid cancer].
    Kopczyńska E; Junik R; Tyrakowski T
    Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.
    Penman CL; Faulkner C; Lowis SP; Kurian KM
    Front Oncol; 2015; 5():54. PubMed ID: 25785246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mps1 is associated with the BRAF
    Li Y; Zhang Y; Xiao S; Kong P; Cheng C; Shi R; Wang F; Zhang L; Wang J; Jia Z; Wu S; Liu Y; Guo J; Cheng X; Cui Y; Liu J
    Oncol Lett; 2018 Jun; 15(6):9978-9986. PubMed ID: 29805692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting BRAF and RAS in Colorectal Cancer.
    Bellio H; Fumet JD; Ghiringhelli F
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34063682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF alterations in primary brain tumors.
    Maraka S; Janku F
    Discov Med; 2018 Aug; 26(141):51-60. PubMed ID: 30265855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets.
    Knauf JA; Fagin JA
    Curr Opin Cell Biol; 2009 Apr; 21(2):296-303. PubMed ID: 19231149
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Nakayama I; Hirota T; Shinozaki E
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33152998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
    Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
    J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
    Cronise KE; Hernandez BG; Gustafson DL; Duval DL
    Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.
    Acosta AM; Kadkol SS
    Arch Pathol Lab Med; 2016 Nov; 140(11):1290-1296. PubMed ID: 27788045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intracellular signaling mechanisms in thyroid cancer].
    Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
    Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTPN11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human Thyroid Cells Overexpressing BRAF V600E Oncogenic Protein.
    Putlyaeva LV; Demin DE; Uvarova AN; Zinevich LS; Prokofjeva MM; Gazizova GR; Shagimardanova EI; Schwartz AM
    Biochemistry (Mosc); 2020 Jan; 85(1):108-118. PubMed ID: 32079522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
    Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma].
    Zaleśna I; Hartman ML; Czyż M
    Postepy Hig Med Dosw (Online); 2016 May; 70():471-88. PubMed ID: 27180965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.
    Jaiswal BS; Durinck S; Stawiski EW; Yin J; Wang W; Lin E; Moffat J; Martin SE; Modrusan Z; Seshagiri S
    Clin Cancer Res; 2018 Aug; 24(16):4044-4055. PubMed ID: 29760222
    [No Abstract]   [Full Text] [Related]  

  • 39. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers.
    Kunz M; Vera J
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30987166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.